Clinical Trials
33 trialsSerplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
GIVEN
Guangdong Provincial People's Hospital
N-PLANC
Mayo Clinic
InDuRanS
University Hospital, Bonn
BOOST
Pusan National University Hospital
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
Fondazione Ricerca Traslazionale
SURGAN-TKI
The First Affiliated Hospital of Guangzhou Medical University
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
ACCESS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
Tianjin Medical University Cancer Institute and Hospital
POSTILV
Radiation Therapy Oncology Group
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
University of California, San Francisco
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Shanghai Pulmonary Hospital, Shanghai, China
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Shanghai Pulmonary Hospital, Shanghai, China
INNWOP1
Medical University Innsbruck
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
National Cancer Center Hospital East
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
Swiss Cancer Institute
NEOSUN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Neoafa
Fifth Affiliated Hospital, Sun Yat-Sen University
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
Swiss Cancer Institute
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Masonic Cancer Center, University of Minnesota
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
H. Lee Moffitt Cancer Center and Research Institute
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
National Cancer Institute (NCI)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Medical University of Vienna
Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Yale University
SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer
SWOG Cancer Research Network
rAd-p53
Shenzhen SiBiono GeneTech Co.,Ltd
Molecular Profiling in Lung Cancer Patients
Eli Lilly and Company
Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)
Maastricht Radiation Oncology